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ABSTRACT 
Silica mesoporous microparticles loaded with both rhodamine B fluorophore (S1) or 
hydrocortisone (S2), and capped with an olsalazine derivative, are prepared and fully 
characterized. Suspensions of S1 and S2 in water at an acidic and a neutral pH show negligible 
dye/drug release, yet a notable delivery took place when the reducing agent sodium dithionite is 
added due to a hydrolysis of an azo bond in the capping ensemble. Besides, olsalazine 
fragmentation induced 5-aminosalicylic acid (5-ASA) release. In vitro digestion models show 
that S1 and S2 solids are suitable systems to specifically release a pharmaceutical agent in the 
colon. In vivo pharmacokinetic studies in rats show a preferential rhodamine B release from S1 
in the colon. Moreover, a model of ulcerative colitis is induced in rats by oral administration of 
2,4,6-trinitrobenzenesulfonic acid (TNBS) solutions, was also used to prove the efficacy of S2 
for colitis treatment. The specific delivery of hydrocortisone and 5-ASA from S2 material to the 
colon tissue in injured rats markedly lowers the colon/body weight ratio and the clinical activity 
score. Histological studies showed a remarkable reduction in inflammation, as well as an 




Inflammatory bowel disease (IBD) is an idiopathic autoimmune, inflammatory and chronic 
disease. There are essentially two main IBD subtypes: ulcerative colitis (UC) and Crohn’s 
disease (CD). However this classification is not always obvious because clinical and pathologic 
features substantially overlap.
1-11
 The IBD etiology is still poorly understood, but all the facts 
indicate a multifactorial origin, where genetics, environmental, and intestinal microbiota are the 
main factors. Since IBD are chronic diseases with a low mortality, continuous incidence or 
newly diagnosed patients increase the number of prevalent cases. The whole costs of IBD are 
quite overwhelming. More than 1,000,000 of people are estimated to suffer from IBD (just in 
USA), and only the direct medical costs exceeded US$ 6 billion in 2004.
12,13
 In Canada over 
200,000 people suffer IBD, with more than CDN$ 1.2 billion spent on direct healthcare costs per 
year.
14
 Moreover, over 3,000,000 of European patients suffer from IBD, and the direct 
healthcare spent is calculated to be over €5 billion per year.
15
 The biggest contributors in these 
healthcare-related costs are pharmaceuticals, hospitalizations, surgery and outpatient care.
16
 
Moreover, non-direct IBD costs (e.g. lost work productivity), exceed even direct costs. Besides, 
in the last decades, developing countries (in Middle East, South America and Asia) have seen 
an important emergence on IBD incidence and prevalence.
17-21
  
Considering together the above mentioned facts, plus the lack of a definitive solution 
available on the market, the development of new strategies to treat IBD are of interest. 
Conventional IBD therapy includes 5-aminosalicylic acid (5-ASA), corticosteroids and 
immunosuppressants.
22
 Steroids were the cornerstone of ulcerative colitis therapy for several 
years due to their proved anti-inflammatory efficacy. However, the therapeutic efficacy of 
steroids in IBD is controversially affected by serious secondary effects. As an alternative, in the 
last decade, biological agents (especially anti-TNF (tumor necrosis factor) therapies) have been 
introduced to be used in UC/CD patients who failed conventional therapy.
23,24
 As an alternative 
to these therapies, nano- and microparticle as drug carriers for oral administration have been 
tested in experimental colitis models to increase drug efficacy.
25-27
 However, among different 
nano- and microparticles, mesoporous silica particles (MSPs) have still been barely studied as 
carries for IBD treatment.
28,29
 As containers of selected cargo molecules, mesoporous silica 
nano- or microparticles have been broadly studied in recent decades for their promising 
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customizable pore size (within the 2-10 nm diameter range), large load capacity, homogeneous 
porosity, tunable particle, inertness and good thermal stability. Compared to organic 
nanocarriers, mesoporous silica materials are generally more resistant to pH, variations in 
temperature and mechanical stress, which renders them improved capability to protect 
molecules and biomolecules when they come into contact with body fluids. Besides, MSPs can 
be decorated with selected molecular or supramolecular entities to either enhance selectivity to 




Considering the urge to find a better solution for the treatment of IBD, we report herein the 
synthesis and characterization of mesoporous silica microparticles loaded with rhodamine B or 
hydrocortisone and capped with an olsalazine derivative (see Scheme 1). As a consequence of 
the grafting of bulky olsalazine groups on the external surface of the loaded inorganic 
framework, the prepared microparticles are unable to release the entrapped cargo. However, 
when a reducing agent such as sodium dithionite (which mimic the azoreductase enzyme 
activity of the colon microbiota) is present the olsalazine derivative is hydrolyzed and yields 5-
aminosalicylic acid (5-ASA). This hydrolysis process induces pore opening and delivery of the 
entrapped cargo (i.e. rhodamine B or hydrocortisone). As a novelty, one of the prepared 
mesoporous microparticles is able to deliver two drugs at the same time; i.e. hydrocortisone 
(located in the pores of the inorganic silica scaffold) and 5-ASA (product of the hydrolysis of the 
gating olsalazine). The effect of the co-delivery of both drugs is studied in an in vivo IBD rat 
model. The information obtained by parameters such as the clinical activity score, the 
colon/body weight ratio and the histological evaluation, confirms the usefulness of these 
microparticles system to treat IBD. 
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Scheme 1. Representation of rhodamine B (S1) or hydrocortisone (S2) loaded silica 
mesoporous particles capped with an olsalazine derivative. Delivery of both cargos (rhodamine 
B or hydrocortisone) is induced by an azoreductor.  
 
2. EXPERIMENTAL SECTION 
2.1. General Techniques. Transmission electron microscopy (TEM), scanning transmission 
electron microscopy (STEM), thermogravimetric analysis (TGA), N2 adsorption-desorption 
isotherms, powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FTIR), 
nuclear magnetic resonance (NMR), fluorescence spectroscopy and HPLC  techniques were 
used in order to characterize the prepared materials. The instruments used were: JEOL JEM-
1010 microscope for TEM images acquisitions. Bruker D8 Advance diffractometer (CuK 
radiation) for PXRD measurements. TGA/SDTA 851e Mettler Toledo balance for TGA, using air 
(80 mL/ min) as an oxidant atmosphere with the following heating program: heating ramp of 10 
°C/min from 393 to 1273 K, then an isothermal heating step at 1273 K for 30 minutes. 
Micromeritics ASAP 2010 automated analyzer for N2 adsorption-desorption isotherms 
recording, samples were degassed at 120 °C in a vacuum overnight. The specific surface areas 
were calculated from the adsorption data within the low-pressure range using the BET 
(Brunauer–Emmett–Teller) model. Pore size was determined following the BJH (Barrett-Joyner-
Halenda) method. Bruker AV400 spectrometer to measure 
1
H NMR spectra. Bruker Tensor 27 
equipment to record infrared spectra. PerkinElmer EnSpire Multimode Plate Reader for 








































fluorescence measurements. Hitachi LaChrom Elite HPLC with a UV detector (L-2400) and an 
auto-sampler (L-2200) for HPLC analysis, using Kromaphase 100 C18 column (150 mm × 4.6 
mm i.d., 5 μm particle size) for separations. 
2.2. Chemicals. The chemicals tetraethylorthosilicate (TEOS), 1-hexadecyltrimethylammonium 
bromide (CTABr), sodium hydroxide (NaOH), triethanolamine (TEAH3), N-hydroxysuccinimide 
(NHS), N,N′-dicyclohexylcarbodiimide (DCC), (3-aminopropyl)triethoxysilane, rhodamine B, 
triethylamine, hydrocortisone, sodium dithionite and 2,4,6-trinitrobenzene sulfonic acid solution 
(TNBS) were purchased from Sigma-Aldrich. Sodium acetate anhydrous, potassium chloride, 
sodium dihydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen 
phosphate, hydrochloric acid and all the solvents were provided by Scharlab. Olsalazine sodium 
salt (Mordant yellow 5) was purchased from Molekula. The animal facilities supplied isoflurane 
pentobarbital (dolethal
®
). All the chemicals were used as received. 
2.3. Synthetic protocols.  
2.3.1. Synthesis of mesoporous silica microparticles (S0). We used the “atrane route” to 
synthesize the micro-sized mesoporous silica particles.
39
 In a typical synthesis, TEAH3 (25.8 g, 
0.17 mol) and sodium hydroxide (2 mL, 6 M) were mixed and the obtained solution was heated 
to 120 
o
C and then cooled down to 70 
o
C. Afterward, TEOS (11 mL, 0.045 mol) was added to 
the initial solution that was then heated to 120 
o
C. Next, solution was left to cool down and the 
surfactant CTABr (4.7 g, 0.013 mol) was added at 118 °C. At this time, distilled water (80 mL) 
was slowly added under vigorous stirring at 70 °C. The resultant mixture was aged at 100 
o
C in 
an autoclave for 24 h. The obtained powder was filtrated and washed with abundant water. In 
the last step of the protocol, the solid is dried at 70 °C. To obtain the solid (S0), a calcination 
process at 550 ºC is performed in an oxidant atmosphere during 5 h in order to remove the 
surfactant template from the as-synthesized microparticles. 
2.3.2. Synthesis of 1a. Olsalazine sodium salt (0.5 g, 1.65 mmol) was dissolved in an acidic 
solution of pH≈0 (28.5 mL of distilled water and 1.5 mL 37% HCl solution). The resultant 
solution was stirred for 5 min at room temperature and then centrifuged. The supernatant was 
discarded and the resulting protonated product (1a, 0.45 g, 1.49 mmol, 90% yield) was 
recovered and dried at 70 
o
C for 24 h. This protocol was repeated 4 times. 
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2.3.3. Synthesis of 1. DCC (1.04 g, 5 mmol) and NHS (0.59 g, 5 mmol) were dissolved in 
anhydrous THF (25 mL). Afterward, this mixture was then poured over a solution of compound 
1a (1.53 g, 5 mmol) in anhydrous THF (25 mL). The crude reaction was stirred during 5 h at 
room temperature in an argon atmosphere. A white-yellowish precipitate of dicyclohexylurea 
(DCU) was discarded by centrifugation. The supernatant was left stirring for 15 h in an argon 
atmosphere at room temperature. After 15 h the crude reaction was recentrifuged to remove the 
newly formed DCU. Then, (3-aminopropyl)triethoxysilane (1b, 1.2 mL, 5 mmol) was slowly 
added to the crude reaction and was stirred for a further 24 h period (room temperature, argon 
atmosphere). The solvent was removed using a rotary evaporator to isolate the final product 1 
(yellow-orange oil, 2.05 gr, 4.05 mmol, 80% yield). 
1
H NMR (400 MHz, DMSO-D6):  = 8.31 (d, 
2H), 7.98 (dd, 2H), 7.05 (d, 2H), 3.65 (m, 6H), 3.36 (t, 2H), 1.67 (m, 2H), 1.17 (m, 9H), 0.68 (t, 
2H) ppm. HRMS-EI m/z: calcd for C23H31N3O8Si: 505.1880; found: 436.3410 (M-
2(CH3CH2OH)+Na) and 391.2828 (M-3(CH3CH2OH)+Na). 
2.3.4. Synthesis of S1. Solid S0 (1 g) was suspended in a THF (40 mL) solution containing 
rhodamine B (400 mg, 0.8 mmol/g of solid) under argon. Suspension was stirred at room 
temperature overnight. Afterward, compound 1 (2.05 g, 4.05 mmol/g of solid) was dissolved in 
anhydrous THF (25 mL) and this mixture was added to the solid/rhodamine B suspension and 
then stirred for 6 h at room temperature in an argon atmosphere. S1 particles were isolated as a 
red solid, washed with H2O and EtOH, and finally dried in a vacuum for 24 h. 
2.3.5. Synthesis of S2. Solid S0 (1 g) was suspended in 40 mL of THF/hydrocortisone solution 
(296 mg, 0.8 mmol/g of solid) under argon. Suspension was stirred at room temperature 
overnight. Next, compound 1 (2.05 g, 4.05 mmol/g of solid) was dissolved in anhydrous THF (25 
mL) and was then added to the solid/hydrocortisone suspension. The obtained suspension was 
stirred under argon and at room temperature during 6 h. S2 particles were isolated as a yellow 
solid, washed with EtOH and H2O, and finally dried for 24 h in a vacuum. 
2.4. Controlled release studies. The controlled release behavior of solids S1 and S2 at pH 
values found along the gastrointestinal tract (GIT) (2.0, 4.5 and 7.4) and in the presence of a 
chemical reducing agent (sodium dithionite), to simulate the azo-reductive environment, were 
assessed. For this purpose, corresponding solid (2 mg) was suspended in 2 mL of the aqueous 
solution at the selected pH. Aliquots were taken at scheduled times up to 24 h and centrifuged 
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to discard the solid before analyzing. The controlled release performances of both solids were 
tested under in vitro digestion conditions using simulated solutions for GIT fluids including 
saliva, gastric juice, duodenal juice, bile and colon (in which azoreductor agent sodium dithionite 
was added for colon reducing environment simulation). In vitro digestion assays were performed 
with 2 mg of solid S1 or S2 at 37 
o
C (simulating the body temperature in humans) and shaken 
(100 rpm) to obtain homogeneous suspensions of microparticles. Digestions started by the 
addition of 320 µL of simulated saliva fluid (pH = 6.8  0.1) and incubating during 5 min. Next, 
630 µL of simulated gastric juice was added and the mixture was stirred 2 h (total volume of 950 
µL and pH = 1.3  0.2). Then, 630 µL of simulated duodenal juice, 320 µL of bile and 100 µL of 
a bicarbonate solution (1 M) were added simultaneously (total volume of 2 mL and pH = 6.0  
0.5). The resulting solution was stirred during 2 h. Finally, colon fluid was simulated with the 
addition of 2 mg/mL of sodium dithionite to the last mixture (total volume of 2 mL pH = 6.0  
0.5). Aliquots were collected at scheduled times up to 28 h (4 h approximately to reach the 
colon, plus 24 h of colon residence time), centrifuged, and analyzed. In order to determine the 
amount of cargo delivered from S1 microparticles, supernatants were loaded into 96-well plate 
and then the rhodamine B emission at 572 nm (upon excitation at 555 nm) was measured. The 
amount of hydrocortisone released from S2 microparticles was assessed from the supernatants 
using an HPLC. The released 5-ASA was also analyzed by HPLC (vide infra). 
2.5. 5-ASA and hydrocortisone quantification. HPLC (with a reverse-phase column) was 





 The HPLC equipment used was a Hitachi LaChrom Elite liquid chromatograph 
connected to an auto-sampler and a UV detector (L-2200 and L-2400, respectively). For both 
analytes, a C18 column (Kromaphase 100 of 150 mm × 4.6 mm i.d., 5 μm particle size) was 
used for separations. For the 5-ASA determinations, mobile phase: (A) 50 mM sodium 
phosphate / (B) methanol, isocratic program: 90% A / 10% B for 15 min. The wavelength of the 
UV detector was set at 365 nm. For hydrocortisone determinations, mobile phase: (A) water / 
(B) acetonitrile, isocratic program: 70% A / 30% B for 15 min. The UV wavelength of the UV 
detector was set at 245 nm. Both analytes were quantified using a calibration curve (peak area 
vs. analyte concentration). The used method was validated using a recovery study. At this 
respect, simulated GIT fluids were spiked with both analytes (5-ASA or hydrocortisone) at five 
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different concentrations. The recovery values were estimated from the determined 
concentration vs. the amounts of 5-ASA or hydrocortisone added. All the recovery values were 
near to 100%. 
2.6. In vivo studies. These studies followed the Principles of Laboratory Animal Care and were 
approved by the Institutional Ethics Committee of the University of Valencia (according to RD 
1201/2005). For the in vivo studies male Wistar rats (aged 8-12 weeks and with an weight in the 
270-330 g interval) were used. Animals were housed in an air-conditioned room (12 h light/dark 
cycles, 22 ± 3 ºC, 55 ± 5% humidity) and were allowed free access to laboratory chow and 
water during all the time of the studies. 
2.6.1. In vivo pharmacokinetic studies. In a first step, male Wistar rats (with an average 
weight of 300±30 g) were anesthetized to facilitate the cannula implantation 24 h before the 
experiment. Then, in a second step, a previously reported method for jugular vein permanent 
cannulation was followed.
42
 The implanted cannula allowed blood sampling. The animals were 
randomly ascribed (n= 8-10) to different groups: Group 1: 1 mL of rhodamine B solution (750 
µg/mL in saline solution) was given orally. Group 2: 1.75 mL of a S1 suspension (containing 30 
mg of solid which should deliver about 750 µg of rhodamine B) was given orally. Blood samples 
(0.6-0.7 mL) were drawn with heparinized syringes and replaced by heparinized saline (10 
IU/mL), at previously established sampling time (up to 4 h). Plasma samples were centrifuged 
(10,000 rpm, 10 min) and supernatant was stored at -20 °C until analyzed by HPLC. A 
fluorescence detector, with excitation and emission wavelength fixed at 225 and 535 nm 
respectively, was used. The solvent delivery system (Alliance System, Waters 2695) was used 
to provide a mobile phase 70:30 v/v of trifluoroacetic acid aqueous solution (pH 3)-acetonitrile. 
The stationary phase was a Waters model Nova Pak C-18 (150 mm length, 3.9 mm in diameter 
and particle size of 4 μm) column preceded by a Teknocroma TCR-C130-B pre-column. Flow 
rate was set at 1 mL/min and the injection volume was 90 µL for in vivo samples. Retention time 
of rhodamine B was 2.5 min. Analytical method was validated in terms of selectivity, specificity, 
precision, linearity and accuracy. After 4 h, rat subjects were euthanized and the cecum, colon 
tissues and feces were extracted and treated in order to determine rhodamine B amount. The 
analyzed rhodamine B corresponded to that released from S1 particles in the GIT of subjects 
(S1 release was not forced in vitro). 
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2.6.2. In vivo efficacy studies. 
2.6.2.1. Inducing colonic inflammation. Several slight modifications were introduced in the 
method described by C. Mura et al. to induce the chronic inflammation model in colon rat.
43
 For 
this purpose, rats were indistinctly separated in different treatment groups (having free access 
to water) and were then anaesthetized with isoflurane. TNBS solution in 59% v/v ethanol (0.6 
mL, 78 mg/kg body weight) was instilled into the lumen of the colon using a graduated rubber 
cannula inserted rectally into the colon (taking into account that the tip was 8 cm proximal to the 
anus). After the induction procedure, the development of inflammation was monitored daily for 
the next 10 days that the assays lasted. Rats were sacrificed using an overdose of isoflurane at 
the end of the 10th day (after induction with TNBS). Inflammation development was evaluated 
through determination of the clinical activity score, colon/body weight ratio and also studying 
changes in tissue histology. 
2.6.2.2. Treatment study design. Rats were distributed into four groups: Group 1 (positive 
control group, 3 rats) with saline solution as treatment; Group 2 (8 rats) treated with a 
suspension of S0 (empty mesoporous silica microparticles); Group 3 (8 rats) treated with 
hydrocortisone solution; Group 4 (8 rats) treated with an aqueous suspension of S2 
microparticles. The hydrocortisone dose that groups 3 and 4 received (5.58 mg/kg/day) was 
calculated from the dose normally used for humans.
44
 All the treatments were carried out using 
an oral gavage once a day during 3 days in the most intensive inflammation period (days 3, 4 
and 5 after TNBS administration). Groups and treatment are summarized in Table 1. 
 
Table 1. Treatment groups. 
Group 1 Group 2 Group 3 Group 4 
saline solution 
(1.5 mL) 
60 mg of S0 in 
1.5 mL 
1.5 mg hydrocortisone in 1.5 mL 30 mg S2 in 1.5 mL 
 
2.6.2.3. Clinical activity score system. A clinical score that assessed weight loss, stool 





Table 2. Clinical activity score system. 
CONTROL RANGE SCORE 







Well-formed pellets 0 
Pasty and semi-formed stools 2 
Liquid stools or absence 4 
BLEEDING 
No blood 0 
Positive finding 2 
Gross bleeding 4 
 
The sum of these scores resulted in the clinical activity which ranged from 0 (healthy animal) to 
12 (higher colitis activity). An activity score of 12 was assigned to rats that died or had to be 
sacrificed before day 10. 
2.6.2.4. Assessing colonic injury and inflammation. Rats were monitored during the 10 days 
period of the assay and, finally, the clinical activity score of colitis was evaluated. On day 10 
after administering TNBS, rats were sacrificed with isoflurane to obtain the distal colon for 
subsequent processing and analyzing. The samples from inflamed tissue were excised to 
calculate C/B ratio, being C the distal colon weight, and B the body weight. Besides, an 
histological evaluation was also carried out. 
2.6.2.5. Determining the colon/body weight ratio. After animal scarification, the distal colon 
was extracted and longitudinally opened along the mesenteric edge. Then, colon was washed 
with a 0.9% (w/v) saline solution, weighted and placed on a glass plate with the mucosal 
surface lying upward.
46
 The 8 cm segment distal colon weight ratio was calculated as an index 
of colonic tissue edema. 
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2.6.2.6. Histological evaluation. A 3 cm sample from distal colon (and a similar portion from 
proximal part) were excised from each subject and maintained in 4% (v/v) p-formaldehyde for 
24 h. Afterward, samples were changed to a 0.4% (v/v) p-formaldehyde medium in order to 
perform the microscopic studies. These colonic tissue samples were routinely processed and 
then embedded in paraffin. Then, longitudinal sections of 5 µm were stained with eosin and 
hematoxylin. Microscopic assessment by light microscope was performed blind on coded slices. 
2.6.2.7. Statistical analysis. Non-parametric U-Mann-Whitney and Kruskal-Wallis tests were 
performed to assess the differences among groups using SPSS v.22.0 (SPSS Inc., USA) on 
Windows. 
 
3. RESULTS AND DISCUSSION 
3.1. Synthesis of mesoporous silica microparticles functionalized with molecular gates. 
The mesoporous silica carrier was synthesized following previously reported procedures with 
minor adjustments.
39
 In this synthetic protocol, tetraethylorthosilicate (TEOS) was employed as 
the source of silica and 1-hexadecyltrimethylammonium bromide (CTABr) as a structure 
directing agent. The resulting white powder was rinsed and then calcined (in order to remove 
the CTABr template). This protocol yielded the mesoporous silica microparticles S0. Pores in S0 
where loaded with a selected dye (rhodamine B) or hydrocortisone and then the external 
surface of both microparticles was functionalized with the olsalazine derivative 1. This 
procedure yielded the final solids S1 (loaded with rhodamine B) and S2 (containing 
hydrocortisone) as depicted in Scheme 1. The pores of S1 and S2 were expected to be capped 
due to the presence of bulky azoderivative 1 anchored to the external surface of microparticles. 
Besides, rhodamine B or hydrocortisone release should be observed in the presence of 
azoreductor agents such as azoreductase enzymes, produced by colon bacteria, or chemical 
reducing species.  
The synthesis of azo derivative containing trialkoxysilane moieties (1) was carried out using a 
two-step sequence (see Scheme 2). First olsalazine sodium salt was protonated to yield the 
free acid (1a), which was then reacted with (3-aminopropyl) triethoxysilane (1b). The final azo 
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Scheme 2. Synthetic route used to prepare 1. 
 
3.2. Characterization of the final materials. Solids S0, S1 and S2 were characterized using 
powder X-ray diffraction (PXRD), transmission electron microscopy (TEM), thermogravimetric 
measurements (TGA), and N2 adsorption-desorption isotherms. The PXRD pattern of the as-
synthesized microparticles showed four reflections indexed as (100), (110), (200) and (210) 
Bragg peaks typical of a mesoporous material with a hexagonal order. A marked shift of the 
(100) reflexion in calcined material S0 was observed. This shift was ascribed to silanol groups 
condensation during the calcination step. Moreover, the preservation of the (100) reflection in 
the PXRD patterns of S1 and S2 microparticles showed that the mesoporous structure was 
preserved during the loading process and functionalization with 1. TEM images of S0 and S2 
also showed the typical porosity of mesoporous silica materials, which confirmed that there was 
no framework modification (data not shown). 
The N2 adsorption-desorption measurements on the calcined solid (S0) showed a type IV 
isotherm, typical of the mesoporous silica materials. This isotherm presented at intermediate 
P/P0 values (0.2-0.4) an adsorption step. From the adsorption branch of the isotherm the values 




) and pore diameter (2.55 nm) were calculated. Besides, the pore 
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diameter estimated from the TEM images agreed with this calculated value. The total specific 




) was evaluated using the Brunauer–Emmett–Teller 
(BET) model. On the other hand, the N2 adsorption-desorption isotherms of S1 and S2 
microparticles were typical of mesoporous systems with partially filled mesopores. When 
compared with S0, both, the specific surface area and adsorbed N2 volume were clearly 
reduced (see Table 3). The loading of pores with rhodamine B (for S1) or hydrocortisone (for 
S2), and the grafting of olsalazine derivative 1 onto the external surface accounted for the 
reduction in the BET surface observed for both solids. 
 




















S0 1193 0.98 2.55 
S1 200 0.06 - 
S2 770 0.35 - 
a
 Total pore volume estimated using the BJH model. 
b
 Pore size according to the BJH model applied to the adsorption branch of the isotherm (for 
P/P0 < 0.6) which can be assigned to the mesopores generated by the surfactant. 
 
 
Table 4. Total organic matter (in g) content per gram of SiO2, olsalazine derivative 1 (in g) 
content per gram of SiO2, dye or drug (hydrocortisone: HC) released (in µg) per mg of solid and 











S1 0.24 0.16 21.50 107 
S2 0.19 0.11 24.36 93 
 
Thermogravimetric analysis and 
1
H NMR measurements were employed to assess the 
organic content in S1 and S2 (see Table 4). The amount of total organic matter was larger in S1 
than in S2, which agrees with the larger specific surface found for S2 (see Table 3), indicating 
that the loading of the mesoporous support with rhodamine B in S1 was more efficient than for 
hydrocortisone in S2. The amounts of olsalazine derivative grafted onto the outer surface of S1 
and S2 were determined by 
1
H NMR measurements. For this purpose, the corresponding solid 
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was dissolved in NaOD/D2O using (CH3CH2)4NBr as internal standard. Moreover, HPLC was 
used to quantify the amount of 5-ASA released. In the presence of a reducing agent (vide infra) 
S1 and S2 were able to deliver 107 µg/mg and 93 µg/mg of 5-ASA, respectively. FT-IR analysis 
on S2 revealed the presence of typical amide signals at 1633 cm
-1
 (carbonyl), 1594 cm
-1
 (N-H 
torsion) and 1486 cm
-1
 (C-N stretching), and azo signal at 1558 cm
-1
 (data not shown). 
3.3. Payload delivery from S1 and S2. The cargo release (rhodamine B or hydrocortisone) 
from solids S1 and S2 was evaluated at acidic pH (2.0 and 4.5) and at neutral pH (7.4) in the 
absence of in the presence of sodium dithionite (an azoreductor agent). These pH values were 
selected bearing in mind typical pH values for gastric juices (pH 2.0), transition from stomach to 
the intestine (pH 4.5) and intestine (pH 7.4). Cargo release profiles for S1 and S2 microparticles 
are shown in Figure 1a and 1b, respectively. Aqueous suspensions of S1 and S2 showed poor 
rhodamine B (S1) or hydrocortisone (S2) release at acidic and neutral pHs. However, a marked 
delivery of the entrapped payload (rhodamine B from S1 and hydrocortisone from S2) was seen 
at pH 7.4 when sodium dithionite was present, which showed a sustained release profile that 
reached ca. 90% (for S1) and 80% (for S2) of the maximum dye/drug delivered after 6 h. The 
observed cargo release was ascribed to the presence of the azoreductor agent (sodium 
dithionite), which is able to reduce the azo groups in the capping molecule 1. This azo group 
reduction resulted in pore opening and rhodamine B (S1) or hydrocortisone (S2) release. The 
maximum rhodamine B release from S1 was ca. 21.50 µg/mg solid, in the presence of an 
azoreductor (pH = 7.4). Under the same experimental conditions, the maximum hydrocortisone 
release from S2 was ca. 24.36 µg/mg solid. The release of 5-ASA in the absence of the 
azoreductor agent was negligible (at pH of 2.0, 4.5 and 7.4), although a clear cargo release was 
attained after 1 h for S1 and S2, respectively, when sodium dithionite was present. To conclude, 
both pharmaceutical active compounds (i.e. hydrocortisone and 5-ASA) were released at a 




Figure 1. (a) Release profiles of rhodamine B from S1 microparticles in water at pH ≈ 2 
(square), pH ≈ 4.5 (circle), pH ≈ 7.4 (triangle) and pH ≈ 7.4 in the presence of sodium dithionite 
(2 mg/mL) (cross). (b) Release kinetics of hydrocortisone (black) and 5-ASA (red) from S2 
microparticles in water at pH ≈ 2 (square), pH ≈ 4.5 (circle), pH ≈ 7.4 (triangle) and pH ≈ 7.4 in 
the presence of sodium dithionite (2 mg/mL) (cross: hydrocortisone, star: 5-ASA). 
 
3.4. In vitro digestion model assay. In a further step the delivery of olsalazine and 5-ASA from 
S2 was thoroughly evaluated in a digestion model using simulated solutions. The used model 
was inspired in that reported by Oomen, and consisted in a procedure of three steps simulating 
the digestive process (from the mouth, through the stomach, and to the small intestine).
47,48
 
Moreover, we added an additional step after the small intestine, in order to simulate digestion at 
colonic area. In a typical experiment, S2 (2 mg) was suspended for 5 min in the simulated saliva 
at 37.5 
o
C, afterwards simulated gastric juice (stomach) was added and the suspension was 
stirred during 2 h. Next, the simulated small intestine fluid (duodenal simulated juice, bile and 
bicarbonate solution) was added and the mixture was stirred for 2 h. Finally, addition of sodium 
dithionite simulated the azoreductor colon environment. This final suspension was left for 24 h. 
The release of hydrocortisone and 5-ASA from S2 was quantified by HPLC under the conditions 





Figure 2. Release kinetics of the hydrocortisone (HC) and 5-ASA from S2 in simulated GIT 
fluids. 
 
As seen in Figure 2, the released hydrocortisone or 5-ASA from S2 was less than 5% in the 
simulated mouth, stomach and small intestine juices, which indicates that acidic media over a 
period shorter than 2 h does not induce hydrocortisone or 5-ASA delivery. In contrast, a clear 
release of both drugs (maximum delivery was 30.44 and 81.25 µg/mg solid for hydrocortisone 
and 5-ASA respectively) was observed when S2 came into contact with the simulated colon 
juice due to the reduction of the azo linkages in the gated material.  
3.5. In vivo pharmacokinetic studies. To test both the specific colon release and systemic 
absorption prevention, in vivo pharmacokinetic studies with S1 microparticles were performed. 
Rats in group 1, which were administered with a rhodamine B solution, showed plasma levels of 
rhodamine B with a maximum of 0.45 µg/mL 1 h after administration (Figure 3). Group 2, which 
received formulation S1, showed negligible rhodamine B systemic absorption and no rhodamine 
B was found in plasma (Figure 3). The presence of rhodamine B in the cecum, colon and feces 
was also evaluated. Figure 4 shows significant larger presence of rhodamine B in the colon and 
cecum in rats fed with S1 (Group 2) compared with those treated with rhodamine B (Group 1). 
These results evidence the specific dye/drug delivery to the colon from the systems designed in 
this work, and also demonstrated that systemic absorption was avoided when rhodamine B was 
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encapsulated in S1. Besides, Cmax and Tmax values for rats in groups 1 (administered with 
rhodamine B solution) and 2 (treated with S1) are shown in Table 5. 
 
Figure 3. The rhodamine B concentration (µg/mL) in plasma. For the subjects which received 
rhodamine B solution (Group 1) and those which receiving suspension S1 (Group 2). 
 
Table 5. Cmax and Tmax of both formulations assayed. (n = 4). 




) Cmax (µg/mL) 
Tmax 
(min) 
Group 1 56.92 0.45* 50* 
Group 2 9.21 0.02 250 
Note: * statistically significant differences (p < 0.05) between Group 1 and Group 2  
Cmax (maximal drug concentration), Tmax (time to reach Cmax) of rhodamine B plasma profiles 
were calculated and compared to determine if the prepared suspension modify the dye solution 




Figure 4. Rhodamine B concentration (µg/mL) in the cecum, colon and feces. For the subjects 
that received rhodamine B solution (Group 1) and those administered S1 suspension (Group 2). 
 
3.6. In vivo efficacy studies 
3.6.1. Inducing colonic inflammation. TNBS was used to induce the IBD model in rats. In this 
model, enema administration of TNBS (50% V/V in ethanol) induced IBD-like injuries. The 
reproducibility, simplicity dose- and time-related development of inflammation are the most 
remarkable advantages of this model.
49,50
 Inflammation development was monitored daily. 
During the period of study, individuals suffered weight loss and diarrhoea, but no rectal 
bleeding. 
Figure 5A shows the typical appearance of a healthy colon of rats. Figure 5B shows the 
opened colon of the rats that received saline serum (placebo treatment, Group 1), whereas 
Figures 5C to E show the opened colons of rats after inducing colitis with TNBS and treated 
with S0, hydrocortisone and S2, Groups 2, 3 and 4 respectively. All rats were sacrificed 10 days 
after treatment with TNBS. Colons from Groups 1 (Figure 5B) and 2 (Figure 5C) were strikingly 
similar and both presented a thick rigid bowel and showed necrotic tissue. In colons from 
individuals treated with hydrocortisone (Group 3, Figure 5D) some tissue started to heal, but 
although thickened tissue and necrotic zone had reduced, they were still present. In contrast, 
colons of rats from Group 4 treated with S2 (Figure 5E) generally appeared healthy, and only a 
few presented very small mild injuries. In addition, after the administration of S2, subjects from 
Group 4 gained some weight and presented normal stools, similar to some subjects of Group 3 
(which received hydrocortisone solution). On the other hand, after the administration of saline 
solution or S0, rats from Groups 1 and 2 had diarrhea and lost weight throughout the 
experiment. Figures 6 and 7 showed the effects after oral administration of the different 
formulations on the clinical activity score and the colon/body weight, respectively. 
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Figure 5. Pictures of rat colon 10 days after inducing colitis with TNBS: A healthy control 
(without TNBS administration), B positive control (Group 1, treated with saline serum), C (Group 
2, treated with S0), D (Group 3, administered with hydrocortisone) and E (Group 4, 
administered with S2). 
 
The colon/body weight ratio decreased considerably in rats of Group 4 (treated with S2) 
compared to the control, which received saline solution (Group 1). In contrast no accentuated 
effect was observed on the colon/body weight ratio for subjects treated with S0 particles (Group 
2). Rats in Group 3 (treated with the hydrocortisone solution) had a wide variability, with several 
cases of improvement and several cases without improvement at all (Figure 6). Similar results 
(i.e. wide variability) were found for Group 3 in the clinical activity score (Figure 7). This large 
variation observed for Group 3 can be due to one of the following reasons: a) orally taken 
hydrocortisone is almost absorbed completely before reaching its site of action; b) the dose of 
an administered drug in not enough to allow recovery. In contrast, the S2 formulation allowed 
the release of two drugs, i.e. hydrocortisone (carried inside the mesoporous silica 
microparticles) and 5-ASA (externally anchored to the surface of microparticles), which results 





Figure 6. The colon/body weight ratio of rats with TNBS-induced colitis after receiving 
subsequent treatments: saline solution (Group 1, positive control), S0 (Group 2), hydrocortisone 
(Group 3) and S2 (Group 4). In each box represents the median value, the 25% and 75% 
percentiles, the minimal and maximal values (
a,b 
statistical significant difference (P < 0.05) 
compared to the saline and S0 solid, respectively). 
 
 
Figure 7. The clinical activity score of rats with TNBS-induced colitis after receiving subsequent 
treatments: saline solution (Group 1, positive control), S0 (Group 2), hydrocortisone (Group 3) 
and S2 (Group 4). In each box represents the median value, the 25% and 75% percentiles, the 
minimal and maximal values (
a,b 
statistical significant difference (P < 0.05) compared to the 
saline and S0 solid, respectively). 
 
3.6.2. Histological evaluation. Histological tissue examinations in a healthy control rats, and in 
rats treated with TNBS of different groups: i.e. 1 (saline solution, positive control group); 2 (S0); 
3 (hydrocortisone solution); 4 (S2 formulation) were carried out. Samples were always taken 
from the sacrificed subjects on day 10 after TNBS treatment. The healthy control showed a 
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usual colon structure: i.e. connective tissue and goblet cells (lamina propria, Figure 8A), healthy 
mucosa with enterocytes, muscularis mucosae, normal submucosa and muscularis externa. On 
the other hand, tissues from rats of Groups 1 and 2 showed loss of necrotic mucosa and 
substitution for granulation tissue (see Figure 8B and 8C). Besides, a strong inflammatory 
process was present in the lamina propria, submucosa and muscularis extern in the individuals 
of both groups. Figure 8B and 8C also show the ulceration process with the fibrinoid necrosis of 
the mucosal surface and granulation tissue below necrotic tissue. Rats of Group 3 (treated with 
hydrocortisone) only showed superficial erosion, thinning mucosa (complemented by a 
thickening of muscularis mucosae), and a chronic inflammatory process which affected the 
mucosa and submucosa with an early development of lymphoid follicle. Besides, Figure 8D also 
shows a small number of parts with a normal mucosa structure. However, the presence of 
strong follicular hyperplasia (in the muscularis externa and parts with necrosis), loss of mucosa 
and substitution for granulation tissue, and the inflammation process is also observed in Figure 
8D. The individuals treated with S2 microparticles (Group 4) showed a normal mucosal 
structure with the presence of minor chronic inflammation in muscularis propria (see Figure 8E). 
   
 





Figure 8. Histology of a representative colon specimen of healthy rats (A) and rats after 
inducing colitis with TNBS, treated and sacrificed on day 10: (B) administered with saline 
solution (positive control, Group 1), (C) treated with S0 (Group 2), (D) administered with 
hydrocortisone (Group 3) and (E) treated with S2 (Group 4). 
 
The histological findings indicated that Group 1 individuals (the saline-treated TNBS group) 
showed necrosis, strong inflammation and mucosa loss. Similar results were observed with the 
rats treated with microparticles S0 (Group 2). In contrast, the histological findings of the rats 
treated with S2 (Group 4) showed an intensive regeneration, softer inflammation, and an almost 
normal mucosal structure. The information obtained by the colon/body weight ratio, the clinical 
activity score and the histological evaluation, confirming the usefulness of S2 system to treat 
IBD. Moreover, it can be stated that our formulation improved the results reported in previous 
studies by C.Mura et al., M. Naeem et al. or A. H. Teruel et al., with the added benefit of not 





A novel oral colon drug delivery system is designed and prepared, and its efficiency to treat 
IBD was evaluated in vivo in a TNBS-induced colitis rat model. The prepared system consists of 
mesoporous silica microparticles loaded with either, rhodamine B (S1) or hydrocortisone (S2), 
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and decorated on the external surface with an olsalazine derivative. This olsalazine derivative is 
a bulky azo compound, covalently grafted onto the external surface of the loaded support 
through amide linkages, which yielded drug 5-ASA upon hydrolysis of the azo bonds. Both 
materials (i.e. S1 and S2) remained capped at neutral an acidic pH, yet a remarkable payload 
delivery is evident when sodium dithionite (a reducing agent that mimics the azo-reductase 
enzymes present in colon) was present. Cargo release is a consequence of the sodium 
dithionite-induced reduction of azo bonds in the bulky capping ensemble, whereas 5-ASA is 
also delivered from both microdevices upon the hydrolysis of the olsalazine derivative. In vivo 
pharmacokinetic studies performed with S1 showed specific rhodamine B delivery at colonic 
area. The clinical activity score, the colon/body weight ratio and the histological colon tissue 
evaluation evidenced that rats with chronic colon inflammation and treated with microparticles 
S2 show an improvement in the pathology due to the simultaneous hydrocortisone and 5-ASA 
release. In conclusion, we demonstrate that microparticles reported here can be used to release 
drugs specifically in the last intestine part, while diminishing systemic absorption. Specifically S2 
is a formulation able to treat IBD due to the double drug delivery (i.e. hydrocortisone and 5-ASA 
release) at the colon. 
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